Corporate Presentation

Download June 2025 Presentation

Select Highlights

June 2, 2025

News: STAT6 DC Nomination

View Press Release »
May 18, 2025

ATS Conference: STAT6 Data

Access Poster »
May 8, 2025

SID Conference: BTK Data

Access Poster »

Latest Press Releases

June 2, 2025

Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi

Read More »
May 19, 2025

Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma Model

Read More »
May 7, 2025

Recludix Pharma Presents Preclinical Data on First-in-Class BTK SH2 Domain Inhibitor Demonstrating Powerful BTK Inhibition, Exceptional Selectivity, and Encouraging Efficacy in a Model of Chronic Spontaneous Urticaria

Read More »
February 10, 2025

Recludix Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Read More »
More Press Releases

Events and Presentations

June 30, 2025

Recludix Platform has Unlocked Development of Oral, Reversible Small Molecule Inhibitors of SH2 Domains

View Poster »
May 18, 2025

Highly selective and reversible STAT6 inhibition demonstrates potential for differentiated efficacy and safety profile in type 2 allergic inflammation

View Poster »
May 8, 2025

Novel Inhibitors of the BTK SH2 Domain Selectively and Potently Block BTK Signaling and are Efficacious in Preclinical Models of Chronic Spontaneous Urticaria

View Poster »
December 7, 2023

STAT6 Program Highlighted in Sanofi R&D Day

Access Webcast »
More Events and Presentations

News Coverage Highlights

August 7, 2023

BioCentury: Recludix: targeting STATs via their SH2 domains

Read More »
July 20, 2023

BioWorld:  Recludix enters a potential $1.2B deal with Sanofi

Read More »
July 20, 2023

SCRIP: Sanofi Adds To Immunology Pipeline In Collaboration With Recludix  

Read More »
July 20, 2023

Fierce Biotech: Sanofi pays $125M to go after undruggable inflammatory target with Recludix’s preclinical program

Read More »
July 20, 2023

Endpoints News: Following Dupixent’s rise, Sanofi heads downstream in immunology for $125M small molecule pact with Recludix

Read More »
MENU